Sweet syndrome caused by oral contraceptives

Kazlouskaya, Viktoryia; Junkins‐Hopkins, Jacqueline M.; Wu, Karen; Itenberg, Sarit

doi:10.1111/ijd.12759

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TTO of Sweet's syndrome among our cases was variable, ranging from a few days to several years, with a median TTO of 15 days (range 1–1095). This has also been observed in the literature, with some lesions appearing days, 6,17,29 months, 16,32 or even years after drug administration 33 . Thompson and Monterella 14 found a mean time from G‐CSF initiation to lesion onset of 46 days, 17 days with ATRA and 4 h to 15 days with vaccines.…”

Section: Discussionsupporting

confidence: 60%

“…This has also been observed in the literature, with some lesions appearing days, 6,17,29 months, 16,32 or even years after drug administration. 33 Thompson and Monterella 14 found a mean time from G-CSF initiation to lesion onset of 46 days, 17 days with ATRA and 4 h to 15 days with vaccines. The review of Sweet's syndrome with tyrosine kinase inhibitors by Yang et al 28 found an average TTO of 2 months (range 3 weeks to 6 years).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database

Martin¹,

Trenque²,

Herlem³

et al. 2023

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimSweet’s syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established, however several cases of Sweet’s syndrome have been reported following drug administration.MethodsTo investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet’s syndrome, we performed a case/non‐case study on reports of “acute febrile neutrophilic dermatosis” registered in the French pharmacovigilance database. Reporting Odds Ratio (ROR) with its 95% confidence interval were calculated.ResultsAmong the 994,789 reports recorded in the database, 136 were Sweet’s syndrome. 50.7% of patients were men; median age was 59 years (range 15‐91). 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics, 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet’s syndrome was 15 days (range 1‐1095). Highest ROR were observed with bortezomib (74.04 [40.8‐134.2]), azacitidine (72.14 [29.4‐176.9]), perfilgrastim (67.05 [21.2‐211.6]), azathioprine (55.46 [34.8‐88.4]) and bendamustine (35.84 [11.4‐112.8]).ConclusionPharmacovigilance signals have been observed between the occurrence of Sweet’s syndrome and colony‐stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and encourage reporting any case of drug‐induced Sweet’s syndrome.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 98%

Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database

Martin¹,

Trenque²,

Herlem³

et al. 2023

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Furthermore, the study herein highlights the consistent presence of lymphocytes in all cases of SS evaluated, predominantly localized around the vessels, as was also noted by Jordaan . In fact, we recently have described a case of SS induced by oral contraceptives, and histopathology also showed perivascular lymphocytes . We identified examples of subtle neutrophilic infiltrates, with a predominance of lymphocytes (Figure ).…”

Section: Discussionmentioning

confidence: 64%

Lymphocytes in Sweet syndrome: A potential diagnostic pitfall

Kazlouskaya

Junkins‐Hopkins

2018

J Cutan Pathol

Self Cite

View full text Add to dashboard Cite

Awareness of the lymphocytic component of SS is important to avoid diagnostic errors, especially in subcutaneous lesions of SS, in which the lymphocytic infiltrate predominates in the upper parts of the dermis, while the typical neutrophilic infiltrate may be seen only in the deeper dermis and subcutis. The lymphocytic component may potentially help to differentiate lesions of SS from neutrophilic urticarial dermatosis, which has not been reported to contain a significant lymphocytic population.

show abstract